100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44CA165314
Award Date
1/1/12
Completion Date
8/31/25
Dollars Obligated
$10M
Overview
Activity
14
Transactions
14
Subawards
Similar Awards
Federal Agency
National Cancer Institute
Awardee
Imcare Biotech, Inc. (K68HYAKNBMX5)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Update #1
Update #2
A NOVEL DIAGNOSTIC BIOMARKER FOR HEPATOCELLULAR CARCINOMA(HCC)
Posted 3/31/15
5
1
2
3
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
A NOVEL DIAGNOSTIC KIT FOR HEPATOCELLULAR CARCINOMA - PROJECT SUMMARY IMCARE BIOTECH IS SEEKING TO COMMERCIALIZE SERAVUE, AN ELISA-BASED DIAGNOSTIC SYSTEM THAT IS ABLE TO IDENTIFY BOTH EARLY AND LATE STAGE HEPATOCELLULAR CARCINOMA (HCC) WITH HIGH SENSITIVITY AND SPECIFICITY. WITH NCI- SUPPORTED PHASE I AND II SBIR AWARDS PLUS INTERNAL AND EXTERNAL INVESTOR SUPPORT, IMCARE COMPLETED THE TECHNICAL DEVELOPMENT OF THE SERAVUE PRODUCT AND NOW REQUESTS PHASE IIB SBIR SUPPORT TO CONDUCT A PROSPECTIVE CLINICAL STUDY REQUIRED FOR A 510(K) FILING AND SUBSEQUENT REGULATORY CLEARANCE. COMMERCIALIZATION OF SERAVUE HAS THE POTENTIAL TO SUBSTANTIALLY IMPROVE EARLY DETECTION OF HCC IN PATIENTS UNDERGOING SURVEILLANCE DUE TO HIGH-RISK CONDITIONS, THEREBY ENSURING TIMELY, EFFECTIVE TREATMENT AND GREATLY INCREASING SURVIVAL. HCC, THE MOST COMMON AND DEADLIEST FORM OF LIVER CANCER, HAS A 5-YEAR SURVIVAL RATE OF LESS THAN 15% AND IS DIRECTLY RESPONSIBLE FOR HUNDREDS OF THOUSANDS OF DEATHS WORLDWIDE EACH YEAR. HCC IS TYPICALLY DIAGNOSED AT A LATE STAGE WHEN TREATMENTS ARE LARGELY INEFFECTIVE, RESULTING IN POORER PROGNOSIS, BUT EARLY DIAGNOSIS AND TREATMENT CAN INCREASE 5-YEAR SURVIVAL RATES TO >70%. THUS, INDIVIDUALS KNOWN TO BE AT HIGH RISK FOR HCC-INCLUDING PATIENTS WITH LIVER CIRRHOSIS OR CHRONIC HEPATITIS B/C-UNDERGO HCC SURVEILLANCE EVERY 3 TO 6 MONTHS TO IMPROVE THE CHANCES OF CATCHING THE DISEASE EARLY. CURRENT SURVEILLANCE METHODS HAVE SIGNIFICANT DRAWBACKS INCLUDING COST, BURDEN, POOR DETECTION OF EARLY DISEASE, AND INADEQUATE SENSITIVITY AND SPECIFICITY. TO ADDRESS THE NEED FOR A BETTER SURVEILLANCE TOOL, WE DEVELOPED SERAVUE, A MINIMALLY-INVASIVE, ACCURATE, CONSISTENT, AND INEXPENSIVE TEST FOR LIVER CANCER-SERINE PROTEASE INHIBITOR KAZAL (LC-SPIK), A PROTEIN SPECIFICALLY SECRETED BY HCC CELLS. IN PHASE I AND PHASE II STUDIES, IMCARE CONFIRMED TWO CRITICAL FEATURES OF SERAVUE: 1) IT DISTINGUISHES HCC FROM OTHER LIVER DISEASES, NON-LIVER DISEASES, AND HEALTHY SUBJECTS AND 2) IT IS SIGNIFICANTLY MORE SENSITIVE AND SPECIFIC THAN ALPHA FETOPROTEIN (AFP), THE MOST COMMON BIOMARKER TEST FOR HCC. IN THIS PHASE IIB SBIR, IMCARE PROPOSES TO CONDUCT A CLINICAL STUDY TO SUPPORT A 510(K) FILING FOR THE CLEARANCE OF SERAVUE AS CLASS II MEDICAL DEVICE. AIM 1. DEMONSTRATE THE FEASIBILITY AND EFFECTIVENESS OF USING SERUM LEVELS OF LC-SPIK TO ASSESS THE RISK OF DEVELOPING HCC FOR PATIENTS WITH CHRONIC LIVER DISEASE. PER FDA GUIDANCE, THE BLOOD BIOMARKER DCP WILL BE USED AS THE PRIMARY PREDICATE. PRIMARY ENDPOINTS: SENSITIVITY AND SPECIFICITY COMPARED TO DCP. SECONDARY ENDPOINT: CALCULATED RELATIVE RISK OF DEVELOPING HCC COMPARED TO DCP. AIM 2. PURSUE CMS REIMBURSEMENT AND SUBMIT A 510(K) APPLICATION. MILESTONES: 1) ADDITIONAL REQUIREMENTS FOR CMS REIMBURSEMENT IDENTIFIED AND 2) 510(K) FILING SUBMITTED. IMPACT: SUCCESSFUL COMPLETION OF THESE MILESTONES IS EXPECTED TO SUPPORT FDA CLEARANCE OF SERAVUE, WHICH WILL PROVIDE AN EARLY DETECTION AND SURVEILLANCE TOOL FOR HCC THAT PROVIDES BETTER EFFICACY, LOWER COST, AND LOWER BURDEN THAN CURRENT TOOLS. COMMERCIALIZATION OF SERAVUE IS EXPECTED TO SAVE LIVES BY INCREASING EARLY DETECTION.
$0
1/9/26
Not listed
A NOVEL DIAGNOSTIC KIT FOR HEPATOCELLULAR CARCINOMA - PROJECT SUMMARY IMCARE BIOTECH IS SEEKING TO COMMERCIALIZE SERAVUE, AN ELISA-BASED DIAGNOSTIC SYSTEM THAT IS ABLE TO IDENTIFY BOTH EARLY AND LATE STAGE HEPATOCELLULAR CARCINOMA (HCC) WITH HIGH SENSITIVITY AND SPECIFICITY. WITH NCI- SUPPORTED PHASE I AND II SBIR AWARDS PLUS INTERNAL AND EXTERNAL INVESTOR SUPPORT, IMCARE COMPLETED THE TECHNICAL DEVELOPMENT OF THE SERAVUE PRODUCT AND NOW REQUESTS PHASE IIB SBIR SUPPORT TO CONDUCT A PROSPECTIVE CLINICAL STUDY REQUIRED FOR A 510(K) FILING AND SUBSEQUENT REGULATORY CLEARANCE. COMMERCIALIZATION OF SERAVUE HAS THE POTENTIAL TO SUBSTANTIALLY IMPROVE EARLY DETECTION OF HCC IN PATIENTS UNDERGOING SURVEILLANCE DUE TO HIGH-RISK CONDITIONS, THEREBY ENSURING TIMELY, EFFECTIVE TREATMENT AND GREATLY INCREASING SURVIVAL. HCC, THE MOST COMMON AND DEADLIEST FORM OF LIVER CANCER, HAS A 5-YEAR SURVIVAL RATE OF LESS THAN 15% AND IS DIRECTLY RESPONSIBLE FOR HUNDREDS OF THOUSANDS OF DEATHS WORLDWIDE EACH YEAR. HCC IS TYPICALLY DIAGNOSED AT A LATE STAGE WHEN TREATMENTS ARE LARGELY INEFFECTIVE, RESULTING IN POORER PROGNOSIS, BUT EARLY DIAGNOSIS AND TREATMENT CAN INCREASE 5-YEAR SURVIVAL RATES TO >70%. THUS, INDIVIDUALS KNOWN TO BE AT HIGH RISK FOR HCC-INCLUDING PATIENTS WITH LIVER CIRRHOSIS OR CHRONIC HEPATITIS B/C-UNDERGO HCC SURVEILLANCE EVERY 3 TO 6 MONTHS TO IMPROVE THE CHANCES OF CATCHING THE DISEASE EARLY. CURRENT SURVEILLANCE METHODS HAVE SIGNIFICANT DRAWBACKS INCLUDING COST, BURDEN, POOR DETECTION OF EARLY DISEASE, AND INADEQUATE SENSITIVITY AND SPECIFICITY. TO ADDRESS THE NEED FOR A BETTER SURVEILLANCE TOOL, WE DEVELOPED SERAVUE, A MINIMALLY-INVASIVE, ACCURATE, CONSISTENT, AND INEXPENSIVE TEST FOR LIVER CANCER-SERINE PROTEASE INHIBITOR KAZAL (LC-SPIK), A PROTEIN SPECIFICALLY SECRETED BY HCC CELLS. IN PHASE I AND PHASE II STUDIES, IMCARE CONFIRMED TWO CRITICAL FEATURES OF SERAVUE: 1) IT DISTINGUISHES HCC FROM OTHER LIVER DISEASES, NON-LIVER DISEASES, AND HEALTHY SUBJECTS AND 2) IT IS SIGNIFICANTLY MORE SENSITIVE AND SPECIFIC THAN ALPHA FETOPROTEIN (AFP), THE MOST COMMON BIOMARKER TEST FOR HCC. IN THIS PHASE IIB SBIR, IMCARE PROPOSES TO CONDUCT A CLINICAL STUDY TO SUPPORT A 510(K) FILING FOR THE CLEARANCE OF SERAVUE AS CLASS II MEDICAL DEVICE. AIM 1. DEMONSTRATE THE FEASIBILITY AND EFFECTIVENESS OF USING SERUM LEVELS OF LC-SPIK TO ASSESS THE RISK OF DEVELOPING HCC FOR PATIENTS WITH CHRONIC LIVER DISEASE. PER FDA GUIDANCE, THE BLOOD BIOMARKER DCP WILL BE USED AS THE PRIMARY PREDICATE. PRIMARY ENDPOINTS: SENSITIVITY AND SPECIFICITY COMPARED TO DCP. SECONDARY ENDPOINT: CALCULATED RELATIVE RISK OF DEVELOPING HCC COMPARED TO DCP. AIM 2. PURSUE CMS REIMBURSEMENT AND SUBMIT A 510(K) APPLICATION. MILESTONES: 1) ADDITIONAL REQUIREMENTS FOR CMS REIMBURSEMENT IDENTIFIED AND 2) 510(K) FILING SUBMITTED. IMPACT: SUCCESSFUL COMPLETION OF THESE MILESTONES IS EXPECTED TO SUPPORT FDA CLEARANCE OF SERAVUE, WHICH WILL PROVIDE AN EARLY DETECTION AND SURVEILLANCE TOOL FOR HCC THAT PROVIDES BETTER EFFICACY, LOWER COST, AND LOWER BURDEN THAN CURRENT TOOLS. COMMERCIALIZATION OF SERAVUE IS EXPECTED TO SAVE LIVES BY INCREASING EARLY DETECTION.
$0
1/15/25
Not listed
A NOVEL DIAGNOSTIC KIT FOR HEPATOCELLULAR CARCINOMA - PROJECT SUMMARY IMCARE BIOTECH IS SEEKING TO COMMERCIALIZE SERAVUE, AN ELISA-BASED DIAGNOSTIC SYSTEM THAT IS ABLE TO IDENTIFY BOTH EARLY AND LATE STAGE HEPATOCELLULAR CARCINOMA (HCC) WITH HIGH SENSITIVITY AND SPECIFICITY. WITH NCI- SUPPORTED PHASE I AND II SBIR AWARDS PLUS INTERNAL AND EXTERNAL INVESTOR SUPPORT, IMCARE COMPLETED THE TECHNICAL DEVELOPMENT OF THE SERAVUE PRODUCT AND NOW REQUESTS PHASE IIB SBIR SUPPORT TO CONDUCT A PROSPECTIVE CLINICAL STUDY REQUIRED FOR A 510(K) FILING AND SUBSEQUENT REGULATORY CLEARANCE. COMMERCIALIZATION OF SERAVUE HAS THE POTENTIAL TO SUBSTANTIALLY IMPROVE EARLY DETECTION OF HCC IN PATIENTS UNDERGOING SURVEILLANCE DUE TO HIGH-RISK CONDITIONS, THEREBY ENSURING TIMELY, EFFECTIVE TREATMENT AND GREATLY INCREASING SURVIVAL. HCC, THE MOST COMMON AND DEADLIEST FORM OF LIVER CANCER, HAS A 5-YEAR SURVIVAL RATE OF LESS THAN 15% AND IS DIRECTLY RESPONSIBLE FOR HUNDREDS OF THOUSANDS OF DEATHS WORLDWIDE EACH YEAR. HCC IS TYPICALLY DIAGNOSED AT A LATE STAGE WHEN TREATMENTS ARE LARGELY INEFFECTIVE, RESULTING IN POORER PROGNOSIS, BUT EARLY DIAGNOSIS AND TREATMENT CAN INCREASE 5-YEAR SURVIVAL RATES TO >70%. THUS, INDIVIDUALS KNOWN TO BE AT HIGH RISK FOR HCC-INCLUDING PATIENTS WITH LIVER CIRRHOSIS OR CHRONIC HEPATITIS B/C-UNDERGO HCC SURVEILLANCE EVERY 3 TO 6 MONTHS TO IMPROVE THE CHANCES OF CATCHING THE DISEASE EARLY. CURRENT SURVEILLANCE METHODS HAVE SIGNIFICANT DRAWBACKS INCLUDING COST, BURDEN, POOR DETECTION OF EARLY DISEASE, AND INADEQUATE SENSITIVITY AND SPECIFICITY. TO ADDRESS THE NEED FOR A BETTER SURVEILLANCE TOOL, WE DEVELOPED SERAVUE, A MINIMALLY-INVASIVE, ACCURATE, CONSISTENT, AND INEXPENSIVE TEST FOR LIVER CANCER-SERINE PROTEASE INHIBITOR KAZAL (LC-SPIK), A PROTEIN SPECIFICALLY SECRETED BY HCC CELLS. IN PHASE I AND PHASE II STUDIES, IMCARE CONFIRMED TWO CRITICAL FEATURES OF SERAVUE: 1) IT DISTINGUISHES HCC FROM OTHER LIVER DISEASES, NON-LIVER DISEASES, AND HEALTHY SUBJECTS AND 2) IT IS SIGNIFICANTLY MORE SENSITIVE AND SPECIFIC THAN ALPHA FETOPROTEIN (AFP), THE MOST COMMON BIOMARKER TEST FOR HCC. IN THIS PHASE IIB SBIR, IMCARE PROPOSES TO CONDUCT A CLINICAL STUDY TO SUPPORT A 510(K) FILING FOR THE CLEARANCE OF SERAVUE AS CLASS II MEDICAL DEVICE. AIM 1. DEMONSTRATE THE FEASIBILITY AND EFFECTIVENESS OF USING SERUM LEVELS OF LC-SPIK TO ASSESS THE RISK OF DEVELOPING HCC FOR PATIENTS WITH CHRONIC LIVER DISEASE. PER FDA GUIDANCE, THE BLOOD BIOMARKER DCP WILL BE USED AS THE PRIMARY PREDICATE. PRIMARY ENDPOINTS: SENSITIVITY AND SPECIFICITY COMPARED TO DCP. SECONDARY ENDPOINT: CALCULATED RELATIVE RISK OF DEVELOPING HCC COMPARED TO DCP. AIM 2. PURSUE CMS REIMBURSEMENT AND SUBMIT A 510(K) APPLICATION. MILESTONES: 1) ADDITIONAL REQUIREMENTS FOR CMS REIMBURSEMENT IDENTIFIED AND 2) 510(K) FILING SUBMITTED. IMPACT: SUCCESSFUL COMPLETION OF THESE MILESTONES IS EXPECTED TO SUPPORT FDA CLEARANCE OF SERAVUE, WHICH WILL PROVIDE AN EARLY DETECTION AND SURVEILLANCE TOOL FOR HCC THAT PROVIDES BETTER EFFICACY, LOWER COST, AND LOWER BURDEN THAN CURRENT TOOLS. COMMERCIALIZATION OF SERAVUE IS EXPECTED TO SAVE LIVES BY INCREASING EARLY DETECTION.
$1.3m
8/28/23
Not listed
A NOVEL DIAGNOSTIC KIT FOR HEPATOCELLULAR CARCINOMA - PROJECT SUMMARY IMCARE BIOTECH IS SEEKING TO COMMERCIALIZE SERAVUE, AN ELISA-BASED DIAGNOSTIC SYSTEM THAT IS ABLE TO IDENTIFY BOTH EARLY AND LATE STAGE HEPATOCELLULAR CARCINOMA (HCC) WITH HIGH SENSITIVITY AND SPECIFICITY. WITH NCI- SUPPORTED PHASE I AND II SBIR AWARDS PLUS INTERNAL AND EXTERNAL INVESTOR SUPPORT, IMCARE COMPLETED THE TECHNICAL DEVELOPMENT OF THE SERAVUE PRODUCT AND NOW REQUESTS PHASE IIB SBIR SUPPORT TO CONDUCT A PROSPECTIVE CLINICAL STUDY REQUIRED FOR A 510(K) FILING AND SUBSEQUENT REGULATORY CLEARANCE. COMMERCIALIZATION OF SERAVUE HAS THE POTENTIAL TO SUBSTANTIALLY IMPROVE EARLY DETECTION OF HCC IN PATIENTS UNDERGOING SURVEILLANCE DUE TO HIGH-RISK CONDITIONS, THEREBY ENSURING TIMELY, EFFECTIVE TREATMENT AND GREATLY INCREASING SURVIVAL. HCC, THE MOST COMMON AND DEADLIEST FORM OF LIVER CANCER, HAS A 5-YEAR SURVIVAL RATE OF LESS THAN 15% AND IS DIRECTLY RESPONSIBLE FOR HUNDREDS OF THOUSANDS OF DEATHS WORLDWIDE EACH YEAR. HCC IS TYPICALLY DIAGNOSED AT A LATE STAGE WHEN TREATMENTS ARE LARGELY INEFFECTIVE, RESULTING IN POORER PROGNOSIS, BUT EARLY DIAGNOSIS AND TREATMENT CAN INCREASE 5-YEAR SURVIVAL RATES TO >70%. THUS, INDIVIDUALS KNOWN TO BE AT HIGH RISK FOR HCC-INCLUDING PATIENTS WITH LIVER CIRRHOSIS OR CHRONIC HEPATITIS B/C-UNDERGO HCC SURVEILLANCE EVERY 3 TO 6 MONTHS TO IMPROVE THE CHANCES OF CATCHING THE DISEASE EARLY. CURRENT SURVEILLANCE METHODS HAVE SIGNIFICANT DRAWBACKS INCLUDING COST, BURDEN, POOR DETECTION OF EARLY DISEASE, AND INADEQUATE SENSITIVITY AND SPECIFICITY. TO ADDRESS THE NEED FOR A BETTER SURVEILLANCE TOOL, WE DEVELOPED SERAVUE, A MINIMALLY-INVASIVE, ACCURATE, CONSISTENT, AND INEXPENSIVE TEST FOR LIVER CANCER-SERINE PROTEASE INHIBITOR KAZAL (LC-SPIK), A PROTEIN SPECIFICALLY SECRETED BY HCC CELLS. IN PHASE I AND PHASE II STUDIES, IMCARE CONFIRMED TWO CRITICAL FEATURES OF SERAVUE: 1) IT DISTINGUISHES HCC FROM OTHER LIVER DISEASES, NON-LIVER DISEASES, AND HEALTHY SUBJECTS AND 2) IT IS SIGNIFICANTLY MORE SENSITIVE AND SPECIFIC THAN ALPHA FETOPROTEIN (AFP), THE MOST COMMON BIOMARKER TEST FOR HCC. IN THIS PHASE IIB SBIR, IMCARE PROPOSES TO CONDUCT A CLINICAL STUDY TO SUPPORT A 510(K) FILING FOR THE CLEARANCE OF SERAVUE AS CLASS II MEDICAL DEVICE. AIM 1. DEMONSTRATE THE FEASIBILITY AND EFFECTIVENESS OF USING SERUM LEVELS OF LC-SPIK TO ASSESS THE RISK OF DEVELOPING HCC FOR PATIENTS WITH CHRONIC LIVER DISEASE. PER FDA GUIDANCE, THE BLOOD BIOMARKER DCP WILL BE USED AS THE PRIMARY PREDICATE. PRIMARY ENDPOINTS: SENSITIVITY AND SPECIFICITY COMPARED TO DCP. SECONDARY ENDPOINT: CALCULATED RELATIVE RISK OF DEVELOPING HCC COMPARED TO DCP. AIM 2. PURSUE CMS REIMBURSEMENT AND SUBMIT A 510(K) APPLICATION. MILESTONES: 1) ADDITIONAL REQUIREMENTS FOR CMS REIMBURSEMENT IDENTIFIED AND 2) 510(K) FILING SUBMITTED. IMPACT: SUCCESSFUL COMPLETION OF THESE MILESTONES IS EXPECTED TO SUPPORT FDA CLEARANCE OF SERAVUE, WHICH WILL PROVIDE AN EARLY DETECTION AND SURVEILLANCE TOOL FOR HCC THAT PROVIDES BETTER EFFICACY, LOWER COST, AND LOWER BURDEN THAN CURRENT TOOLS. COMMERCIALIZATION OF SERAVUE IS EXPECTED TO SAVE LIVES BY INCREASING EARLY DETECTION.
$1.3m
7/25/22
Not listed
A NOVEL DIAGNOSTIC KIT FOR HEPATOCELLULAR CARCINOMA - PROJECT SUMMARY IMCARE BIOTECH IS SEEKING TO COMMERCIALIZE SERAVUE, AN ELISA-BASED DIAGNOSTIC SYSTEM THAT IS ABLE TO IDENTIFY BOTH EARLY AND LATE STAGE HEPATOCELLULAR CARCINOMA (HCC) WITH HIGH SENSITIVITY AND SPECIFICITY. WITH NCI- SUPPORTED PHASE I AND II SBIR AWARDS PLUS INTERNAL AND EXTERNAL INVESTOR SUPPORT, IMCARE COMPLETED THE TECHNICAL DEVELOPMENT OF THE SERAVUE PRODUCT AND NOW REQUESTS PHASE IIB SBIR SUPPORT TO CONDUCT A PROSPECTIVE CLINICAL STUDY REQUIRED FOR A 510(K) FILING AND SUBSEQUENT REGULATORY CLEARANCE. COMMERCIALIZATION OF SERAVUE HAS THE POTENTIAL TO SUBSTANTIALLY IMPROVE EARLY DETECTION OF HCC IN PATIENTS UNDERGOING SURVEILLANCE DUE TO HIGH-RISK CONDITIONS, THEREBY ENSURING TIMELY, EFFECTIVE TREATMENT AND GREATLY INCREASING SURVIVAL. HCC, THE MOST COMMON AND DEADLIEST FORM OF LIVER CANCER, HAS A 5-YEAR SURVIVAL RATE OF LESS THAN 15% AND IS DIRECTLY RESPONSIBLE FOR HUNDREDS OF THOUSANDS OF DEATHS WORLDWIDE EACH YEAR. HCC IS TYPICALLY DIAGNOSED AT A LATE STAGE WHEN TREATMENTS ARE LARGELY INEFFECTIVE, RESULTING IN POORER PROGNOSIS, BUT EARLY DIAGNOSIS AND TREATMENT CAN INCREASE 5-YEAR SURVIVAL RATES TO >70%. THUS, INDIVIDUALS KNOWN TO BE AT HIGH RISK FOR HCC-INCLUDING PATIENTS WITH LIVER CIRRHOSIS OR CHRONIC HEPATITIS B/C-UNDERGO HCC SURVEILLANCE EVERY 3 TO 6 MONTHS TO IMPROVE THE CHANCES OF CATCHING THE DISEASE EARLY. CURRENT SURVEILLANCE METHODS HAVE SIGNIFICANT DRAWBACKS INCLUDING COST, BURDEN, POOR DETECTION OF EARLY DISEASE, AND INADEQUATE SENSITIVITY AND SPECIFICITY. TO ADDRESS THE NEED FOR A BETTER SURVEILLANCE TOOL, WE DEVELOPED SERAVUE, A MINIMALLY-INVASIVE, ACCURATE, CONSISTENT, AND INEXPENSIVE TEST FOR LIVER CANCER-SERINE PROTEASE INHIBITOR KAZAL (LC-SPIK), A PROTEIN SPECIFICALLY SECRETED BY HCC CELLS. IN PHASE I AND PHASE II STUDIES, IMCARE CONFIRMED TWO CRITICAL FEATURES OF SERAVUE: 1) IT DISTINGUISHES HCC FROM OTHER LIVER DISEASES, NON-LIVER DISEASES, AND HEALTHY SUBJECTS AND 2) IT IS SIGNIFICANTLY MORE SENSITIVE AND SPECIFIC THAN ALPHA FETOPROTEIN (AFP), THE MOST COMMON BIOMARKER TEST FOR HCC. IN THIS PHASE IIB SBIR, IMCARE PROPOSES TO CONDUCT A CLINICAL STUDY TO SUPPORT A 510(K) FILING FOR THE CLEARANCE OF SERAVUE AS CLASS II MEDICAL DEVICE. AIM 1. DEMONSTRATE THE FEASIBILITY AND EFFECTIVENESS OF USING SERUM LEVELS OF LC-SPIK TO ASSESS THE RISK OF DEVELOPING HCC FOR PATIENTS WITH CHRONIC LIVER DISEASE. PER FDA GUIDANCE, THE BLOOD BIOMARKER DCP WILL BE USED AS THE PRIMARY PREDICATE. PRIMARY ENDPOINTS: SENSITIVITY AND SPECIFICITY COMPARED TO DCP. SECONDARY ENDPOINT: CALCULATED RELATIVE RISK OF DEVELOPING HCC COMPARED TO DCP. AIM 2. PURSUE CMS REIMBURSEMENT AND SUBMIT A 510(K) APPLICATION. MILESTONES: 1) ADDITIONAL REQUIREMENTS FOR CMS REIMBURSEMENT IDENTIFIED AND 2) 510(K) FILING SUBMITTED. IMPACT: SUCCESSFUL COMPLETION OF THESE MILESTONES IS EXPECTED TO SUPPORT FDA CLEARANCE OF SERAVUE, WHICH WILL PROVIDE AN EARLY DETECTION AND SURVEILLANCE TOOL FOR HCC THAT PROVIDES BETTER EFFICACY, LOWER COST, AND LOWER BURDEN THAN CURRENT TOOLS. COMMERCIALIZATION OF SERAVUE IS EXPECTED TO SAVE LIVES BY INCREASING EARLY DETECTION.
$1.3m
7/25/22